1832 Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.45M Buy
265,437
+1,067
+0.4% +$28.4K 0.01% 391
2025
Q4
$6.58M Buy
264,370
+69,732
+36% +$1.76M 0.01% 408
2025
Q3
$4.96M Sell
194,638
-6,937
-3% -$171K ﹤0.01% 375
2025
Q2
$4.89M Sell
201,575
-612,706
-75% -$14.3M ﹤0.01% 375
2025
Q1
$20.6M Sell
814,281
-9,955,299
-92% -$261M 0.02% 279
2024
Q4
$286M Buy
10,769,580
+5,410,759
+101% +$147M 0.24% 49
2024
Q3
$155M Buy
5,358,821
+2,860,935
+115% +$83.5M 0.12% 93
2024
Q2
$69.9M Buy
2,497,886
+2,487,919
+24,962% +$68.5M 0.06% 158
2024
Q1
$277K Sell
9,967
-97,752
-91% -$2.71M ﹤0.01% 626
2023
Q4
$3.1M Sell
107,719
-4,569,372
-98% -$138M ﹤0.01% 424
2023
Q3
$155M Buy
4,677,091
+2,146,269
+85% +$75.9M 0.22% 78
2023
Q2
$92.8M Buy
2,530,822
+745,976
+42% +$29M 0.11% 112
2023
Q1
$72.8M Sell
1,784,846
-63,974
-3% -$2.76M 0.11% 141
2022
Q4
$94.7M Sell
1,848,820
-49,717
-3% -$2.38M 0.16% 118
2022
Q3
$83.1M Buy
1,898,537
+335,386
+21% +$16.3M 0.15% 131
2022
Q2
$82M Sell
1,563,151
-3,784,557
-71% -$193M 0.14% 133
2022
Q1
$273M Sell
5,347,708
-2,676,438
-33% -$139M 0.39% 61
2021
Q4
$472M Sell
8,024,146
-580,934
-7% -$28.8M 0.83% 34
2021
Q3
$376M Sell
8,605,080
-1,481,599
-15% -$65.6M 0.71% 45
2021
Q2
$394M Sell
10,086,679
-34,075
-0.3% -$1.33M 0.76% 40
2021
Q1
$367M Buy
10,120,754
+432,270
+4% +$15.3M 0.79% 37
2020
Q4
$357M Sell
9,688,484
-746,307
-7% -$27.4M 0.84% 34
2020
Q3
$361M Sell
10,434,791
-1,674,658
-14% -$58.7M 0.94% 27
2020
Q2
$378M Sell
12,109,449
-149,785
-1% -$5.09M 1.13% 19
2020
Q1
$382M Buy
12,259,234
+2,517,593
+26% +$85.8M 1.38% 17
2019
Q4
$362M Buy
9,741,641
+155,339
+2% +$5.53M 1.1% 25
2019
Q3
$329M Buy
9,586,302
+3,914,159
+69% +$142M 1.05% 25
2019
Q2
$234M Buy
5,672,143
+559,068
+11% +$22.2M 0.76% 36
2019
Q1
$206M Sell
5,113,075
-554,698
-10% -$22.2M 0.7% 39
2018
Q4
$234M Sell
5,667,773
-1,329,019
-19% -$55.2M 0.93% 31
2018
Q3
$293M Sell
6,996,792
-1,477,865
-17% -$56.9M 0.95% 31
2018
Q2
$292M Buy
8,474,657
+526,406
+7% +$18M 0.99% 32
2018
Q1
$269M Buy
7,948,251
+263,739
+3% +$9.07M 0.99% 29
2017
Q4
$263M Sell
7,684,512
-838,229
-10% -$28.6M 0.85% 36
2017
Q3
$280M Sell
8,522,741
-978,453
-10% -$31.4M 0.98% 31
2017
Q2
$303M Sell
9,501,194
-101,416
-1% -$3.2M 1.37% 16
2017
Q1
$312M Sell
9,602,610
-10,511,950
-52% -$331M 1.12% 24
2016
Q4
$649M Buy
20,114,560
+11,508,508
+134% +$351M 1.09% 21
2016
Q3
$276M Sell
8,606,052
-190
-0% -$6.35K 1.04% 25
2016
Q2
$289M Buy
8,606,242
+2,347,680
+38% +$74.9M 1.12% 23
2016
Q1
$293M Buy
6,258,562
+1,292,511
+26% +$36.9M 0.71% 40
2015
Q4
$155M Buy
4,966,051
+3,559,106
+253% +$112M 0.67% 41
2015
Q3
$41.5M Sell
1,406,945
-934,010
-40% -$29.9M 0.17% 121
2015
Q2
$73.7M Buy
2,340,955
+434,720
+23% +$14.2M 0.25% 94
2015
Q1
$62.5M Sell
1,906,235
-863,656
-31% -$27.5M 0.24% 104
2014
Q4
$81.7M Buy
2,769,891
+1,178,162
+74% +$33.8M 0.25% 95
2014
Q3
$44.5M Buy
1,591,729
+6,495
+0.4% +$182K 0.15% 147
2014
Q2
$44.5M Sell
1,585,234
-7,952,658
-83% -$227M 0.14% 158
2014
Q1
$289M Buy
9,537,892
+565,145
+6% +$16.9M 0.99% 23
2013
Q4
$261M Buy
8,972,747
+656,289
+8% +$19.1M 1% 25
2013
Q3
$226M Sell
8,316,458
-988,407
-11% -$26.9M 1% 27
2013
Q2
$247M Buy
+9,304,865
New +$257M 1.08% 24

Other funds holding PFE

1832 Asset Management's PFE Position: Q1 2026 in Review

1832 Asset Management increased its Pfizer (PFE) stake by 0.4% in Q1 2026, buying an estimated $28.4K and bringing the position to 265,437 shares worth $7.45M. The position accounts for 0.01% of the portfolio, ranked #391.

1832 Asset Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $649M in Q4 2016. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • 1832 Asset Management held 265,437 shares of Pfizer worth $7.45M as of Q1 2026.
  • 1832 Asset Management bought 1,067 Pfizer shares in Q1 2026, an estimated $28.4K.
  • Pfizer made up 0.01% of 1832 Asset Management's portfolio in Q1 2026, its #391 holding.
  • 1832 Asset Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • 1832 Asset Management's Pfizer position peaked at $649M in Q4 2016.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.